Research

Hormonal

Deregulation of fatty acid synthase (FASN)-catalyzed de novo fatty acid biogenesis drives a 'lipogenic state' that links insulin resistance, type 2 diabetes, and cancer.

Current evidence suggests that high FASN activity contributes to insulin resistance and cancer risk. While not a direct lifestyle intervention, this highlights the importance of managing insulin levels and metabolic health, potentially through lifestyle changes that improve insulin sensitivity, as FASN is a target for future therapeutics.

ModerateSupportsMEDIUM confidence
An emerging paradigm supports the notion that deregulation of fatty acid synthase (FASN)-catalyzed de novo FA biogenesis could play a central role in the pathogenesis of metabolic diseases sharing the hallmark of insulin-resistance.
Javier A. Menéndez et al. · Clinical Chemistry · 2009

Why this rating

The paper is a review of pharmacological and genetic alterations, citing animal models and human observational studies, but lacks large-scale randomized controlled trials for the specific FASN inhibition claim.

Source

Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer

Javier A. Menéndez et al. · Clinical Chemistry · 2009

DOI 10.1373/clinchem.2008.115352

narrative_reviewCited 181×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →